NH SPAC 2 (206640) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NH SPAC 2 (206640) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩111.38 Million ≈ $75.48K USD) by net assets (₩237.02 Billion ≈ $160.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NH SPAC 2 - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how NH SPAC 2's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 206640 liabilities breakdown for a breakdown of total debt and financial obligations.
NH SPAC 2 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NH SPAC 2 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Ganesha Tbk PT
JK:BGTG
|
-0.087x |
|
Chia Chang Co Ltd
TW:4942
|
-0.006x |
|
Mpact Limited
JSE:MPT
|
-0.008x |
|
New England Realty Associates LP
NYSE MKT:NEN
|
-0.034x |
|
The Pinkfong Company
KQ:403850
|
0.052x |
|
Arman Financial Services Limited
NSE:ARMANFIN
|
0.093x |
|
Wallix Group SA
PA:ALLIX
|
0.192x |
|
Equity Commonwealth
NYSE:EQC
|
0.127x |
Annual Cash Flow Conversion Efficiency for NH SPAC 2 (2015–2024)
The table below shows the annual cash flow conversion efficiency of NH SPAC 2 from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of NH SPAC 2.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩223.05 Billion ≈ $151.16 Million |
₩24.88 Billion ≈ $16.86 Million |
0.112x | -35.80% |
| 2023-12-31 | ₩197.42 Billion ≈ $133.79 Million |
₩34.30 Billion ≈ $23.24 Million |
0.174x | +23.18% |
| 2022-12-31 | ₩163.56 Billion ≈ $110.84 Million |
₩23.07 Billion ≈ $15.63 Million |
0.141x | -57.32% |
| 2021-12-31 | ₩151.09 Billion ≈ $102.39 Million |
₩49.93 Billion ≈ $33.83 Million |
0.330x | -11.28% |
| 2020-12-31 | ₩119.86 Billion ≈ $81.23 Million |
₩44.64 Billion ≈ $30.25 Million |
0.372x | +58.88% |
| 2019-12-31 | ₩73.55 Billion ≈ $49.84 Million |
₩17.24 Billion ≈ $11.68 Million |
0.234x | +188.18% |
| 2018-12-31 | ₩65.33 Billion ≈ $44.27 Million |
₩5.31 Billion ≈ $3.60 Million |
0.081x | +522.67% |
| 2017-12-31 | ₩67.87 Billion ≈ $46.00 Million |
₩886.74 Million ≈ $600.93K |
0.013x | -91.67% |
| 2016-12-31 | ₩75.17 Billion ≈ $50.94 Million |
₩11.79 Billion ≈ $7.99 Million |
0.157x | -3.10% |
| 2015-12-31 | ₩59.50 Billion ≈ $40.32 Million |
₩9.63 Billion ≈ $6.53 Million |
0.162x | -- |
About NH SPAC 2
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more